



Closed Trial – status update

**MITO 16b; MANGO-OV2b
ENGOT Ov-17**



A multicenter phase III randomized study with second line chemotherapy ± bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line

Non profit Sponsor: **NCI Naples**
 Lead groups: **MITO MaNGO**
 Final No. of patients: **406**
 Timeline: **FPI: 12/2013 LPI: 11/2016**

 Primary results: Q1-2 / 2018
 Translational: Q4 2018
 Substudies:

Enrollment by Group

GROUP	N. Patients
MITO	206
GINECO	100
MANGO	72
SAKK	17
HeCOG	11
BGOG	0
Total	406